Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Glossary Glossary
The Body Covers: The First International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV
Session 5: Recent Cohort Studies

June 27, 1999

Changes in body shape and laboratory parameters -- including virologic and immunologic -- were assessed in 106 patients with lipodystrophy who had received a protease inhibitor (PI) for at least 9 months. Fifty-two patients were randomized to d4T + ddI + nevirapine (NVP), while 54 remained on PI therapy. CD4+ cell count and CD4% continued to increase in both groups at 24 weeks, although 2 patients in each arm showed viral rebound. There were no significant improvements in dual energy x-ray absorptiometry scans or anthropometric measurements in either group, although cholesterol and triglyceride levels decreased significantly in the NVP arm.

The triglyceride and cholesterol reductions among patients receiving NVP suggests that PI use is associated with metabolic abnormalities. The fact that these reductions were observed despite the use of d4T + ddI therapy shows that these agents are not major contributors to these metabolic abnormalities. However, the follow up time was short; increased differences may be observed over a longer period of follow up and as more patients are enrolled in the study.

Abstract: A Multicenter, Randomized, Open-Label, Comparative Trial of the Clinical, Immunological and Virological Benefit of Switching the PI Nevirapine in HAART-Experienced Patients Suffering Lipodystrophy
Authored by: L. Ruiz, E. Negredo, A. Bonjoch, R. Paredes, J. Romeu, G. Sirera, R.C. Fumaz, L. Zamora, and B. Clotet for the LD Study Group



  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by The Body PRO. Copyright © Body Health Resources Corporation. All rights reserved.


Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

Advertisement